ArticleBMC gastroenterology2025
Association between cumulative uric acid exposure and metabolic dysfunction-associated fatty liver disease.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical Determinants of Serum Uric Acid Levels in Patients with Obesity and Hypertension.Journal of clinical medicine · 2026Article
- Development of a liver stiffness measurement-based nomogram model to identify early CKD risk in patients with MAFLD.BMC gastroenterology · 2026Article
- Metabolomic characteristics and mechanisms of subgingival plaque in MASLD patients with periodontitis.Metabolomics : Official journal of the Metabolomic Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo explore the impact of cumulative uric acid (cum UA) exposure on the incidence of metabolic dysfunction-associated fatty liver disease (MAFLD).
methodsThis prospective cohort study analyzed 21,333 active and retired employees who completed three consecutive health examinations (2006, 2008, 2010), with a mean follow-up time of 6.24 years (SD = 2.59) revealing 8,280 (38.81%) incident MAFLD cases. Participants were stratified into quartiles (Q1-Q4) based on cum UA levels measured across the triennial assessments. Kaplan-Meier survival curves quantified cumulative MAFLD incidence rates across quartiles, followed by multivariable-adjusted Cox proportional hazards regression models to evaluate dose-response relationships between cum UA exposure and MAFLD risk.
resultsFollowing comprehensive adjustment for confounding variables, multivariable analysis revealed progressively elevated hazard ratios for MAFLD development across cum UA quartiles. Compared to the reference quartile 1 (Q1), adjusted HRs (95% CI) were 1.055 (0.989-1.125) for Q2, 1.202 (1.126-1.284) for Q3, and 1.237 (1.154-1.326) for Q4. Restricted cubic spline (RCS) analysis confirmed a significant non-linear dose-response relationship between cumulative UA exposure and MAFLD risk (non-linearity association P < 0.05). The Kaplan-Meier Survival Curves showed significantly diverging cumulative incidence rates across quartiles (Log-rank χ²=87.98; P < 0.001). Incidence densities followed an ascending pattern: 55.07 (Q1), 58.46 (Q2), 66.34 (Q3), and 67.12 cases/1,000 person-years (Q4). Corresponding cumulative incidence rates were 52.20%, 52.49%, 58.29%, and 60.50% respectively. Stratified analysis was performed for gender, abdominal obesity, and smoking. Gender stratification: Q4 HR = 1.315 (1.216-1.422) in males vs. 1.079 (0.953-1.223) in females. Abdominal obesity status: Q4 HR = 1.208 (1.082-1.349) in obese vs. 1.348 (1.237-1.468) in non-obese. Smoking status: Q4 HR = 1.385 (1.238-1.549) in smoking vs. 1.186 (1.087-1.295) in non-smoking. Sensitivity analyses excluding participants with baseline chronic kidney disease (CKD) or follow-up time < 2 years demonstrated comparable risk gradients, confirming the robustness of our primary findings.
conclusionThis study found that cum UA is an independent risk factor for MAFLD. In this longitudinal cohort analysis, both the cumulative incidence and the risk of developing MAFLD increased as the cum UA level rose. Among all the participants, especially subjects who regularly engage in physical exercise, males, individuals with abdominal obesity, and smokers have a higher risk of developing MAFLD.
trial registrationtrial registration number ChiCTRTNC11001489, registration date 20,110,824, registration institution Chinese Clinical Trial Registry, registration site: http://www.chictr.org.cn/index.aspx .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.